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Introduction {#sec1}
============

Vaccinia virus (VACV) is a large double-stranded DNA orthopoxvirus genetically related to variola virus, the causative agent of smallpox ([@bib47]). The antigenic relatedness between orthopoxviruses leads to cross-protection to heterologous infections and explains why VACV was an effective live vaccine against smallpox, which culminated in the eradication of this disease in 1980 ([@bib16]). Following the eradication of smallpox, research with VACV has continued because it is an excellent model for studying virus-host interactions, and because VACV is being developed as a vector for live vaccines against other infectious diseases and as an oncolytic agent. To improve the safety of VACV as a vaccine and to optimize its immunogenicity, there is a need to have a comprehensive understanding of the biology of VACV and its interactions with the host cell.

VACV gene expression is conventionally divided into early, intermediate, and late phases ([@bib47]). Early genes encode multiple proteins that suppress innate and adaptive host immunity, in addition to factors that initiate DNA replication and regulate intermediate class gene expression ([@bib22], [@bib28], [@bib61], [@bib67], [@bib68], [@bib70]). Intermediate genes chiefly encode transcription factors that regulate late gene expression. Late genes encode structural proteins, as well as other proteins incorporated into progeny virions including viral RNA transcription machinery and early gene transcription factors ([@bib4], [@bib30], [@bib60], [@bib88]). Intermediate and late genes are expressed after the onset of genome replication and are collectively termed post-replicative genes ([@bib31], [@bib82]).

A distinct feature of poxviruses is their replication in cytoplasmic "viral factories" without direct involvement of the nucleus, which may engender a particular susceptibility to triggering, and the consequences of a type I interferon (IFN) response ([@bib47]). In addition to encoding multiple proteins that inhibit the interferon regulatory factor 3 (IRF-3) and nuclear factor κB (NF-κB) signaling that would lead to expression of IFN-β ([@bib69]), VACV encodes at least three proteins to directly evade type I IFN. Protein B18 is secreted from infected cells and binds to type I IFNs extracellularly, preventing their engagement with IFN receptors ([@bib9], [@bib74]). Protein H1 dephosphorylates STAT molecules, blocking IFN signal transduction ([@bib48]). Protein C6 co-precipitates with STAT2 and inhibits transcription of IFN-stimulated genes (ISGs) ([@bib73]). C6 can also inhibit activation and nuclear translocation of IRF3, inhibiting IFN production ([@bib79]).

VACV also encodes proteins E3, K3, K1, C7, and C9 that are shown to, or are likely to, antagonize ISGs. Mechanisms of action identified include inhibition of activation of protein kinase R (PKR) or 2′5′-oligoadenylate synthetase (2′5′-OAS), inhibition of phosphorylation of eukaryotic initiation factor 2α to maintain viral protein synthesis, or inhibition of IRF1 (reviewed in [@bib69]). However, only a single report has provided evidence of downregulation of an antiviral restriction factor by VACV. Interferon-induced transmembrane protein 3 (IFITM3) is downregulated during infection to evade antiviral restriction, although neither the viral mechanism of protein modulation, nor the cellular mechanism of VACV restriction by IFITM3, has been determined ([@bib34]).

A systematic quantitative analysis of temporal changes in host and viral proteins throughout the course of productive viral infection can provide dynamic insights into virus-host interaction. These include the prediction of components of innate and adaptive immunity as well as virus-host protein-protein interactions ([@bib84]). Furthermore, an unbiased analysis of proteins targeted by viruses for proteasomal degradation can predict antiviral factors ([@bib49]). Using multiplexed tandem-mass tag (TMT)-based proteomics we measured ∼9,000 host proteins and ∼80% of VACV proteins over seven time points throughout infection, providing a comprehensive temporal view of the host proteome and VACV virome. Our analysis revealed that VACV downregulates 265 proteins, including multiple cell surface collagens and protocadherins, which may act as natural killer (NK) cell ligands. Other insights included the downregulation of multiple ISGs including all canonical IFN-induced proteins with tetratricopeptide repeats (IFITs). Studying infection in the presence or absence of the proteasomal inhibitor MG132 showed that 69% of downregulated proteins were targeted for proteasomal degradation, including histone deacetylase 5 (HDAC5). By generating a temporal system of classification of VACV protein expression, we predicted that the early viral protein C6 targets HDAC5 for degradation, which was confirmed using a mutant virus lacking C6 and a cell line expressing C6. Data presented define HDAC5 as a restriction factor that inhibits the replication of different families of DNA viruses.

Results {#sec2}
=======

Quantitative Temporal Viromic Analysis of Vaccinia Virus Infection {#sec2.1}
------------------------------------------------------------------

To build a global picture of changes in host and viral proteins throughout the course of VACV infection, we infected telomerase reverse transcriptase (TERT)-immortalized primary human fetal foreskin fibroblasts (HFFF-TERTs) with VACV strain Western Reserve (WR) at high multiplicity in biological triplicate. Flow cytometry confirmed that \>95% of cells were infected ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Eleven-plex TMT and triple-stage mass spectrometry (MS3) were used to quantify changes in protein expression over seven time points ([Figure 1](#fig1){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). This quantified 8,991 human proteins and 172/216 viral proteins, providing a global view of changes in protein expression during infection ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Mock and early infection samples clustered separately from intermediate and late infection time points, with changes of the greatest magnitude occurring mostly late during infection ([Figure 1](#fig1){ref-type="fig"}B). Over 18 h of infection, 265 human proteins were downregulated \>2-fold, and 70 human proteins upregulated \>2-fold ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C; [Tables S2](#mmc3){ref-type="supplementary-material"}A and S2B). This approach was validated by confirming the known downregulation of tumor suppressor protein p53 and upregulation of transcription factors Fos, Jun, and EGR1 ([Figure S1](#mmc1){ref-type="supplementary-material"}D) ([@bib12], [@bib66], [@bib83], [@bib91]). Previously unreported findings included degradation of HDAC5 ([Figure 1](#fig1){ref-type="fig"}D). All data are shown in [Table S1](#mmc2){ref-type="supplementary-material"}, in which the worksheet ''Plotter'' enables interactive generation of temporal graphs of the expression of each of the human or viral proteins quantified.Figure 1Quantitative Temporal Analysis of VACV Infection(A) Schematic of experimental workflow for each of three biological replicates. Cells were infected at MOI of 5 or mock infected ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Additionally, one mock and one infected sample were treated for 6 h with the viral DNA replication inhibitor cytosine arabinoside (AraC).(B) Hierarchical cluster analysis of all proteins quantified. An enlargement of three subclusters is shown (right panel), including multiple proteins that were substantially up- or downregulated.(C) Scatterplot of all proteins quantified at 18 h of infection. For all analyses in this manuscript, a mean fold change at each time point was calculated by averaging fold changes from each of the biological replicates in which the protein was quantified. For the purposes of comparison, the 18-h mock sample from each replicate was used, because the 0-, 6-, and 18-h mock samples behaved extremely similarly ([Figure S1](#mmc1){ref-type="supplementary-material"}E). To perform a comprehensive analysis, "sensitive" criteria were employed, examining proteins down- or upregulated \>2-fold on average across all replicates in which the protein was quantified ([Table S2](#mmc3){ref-type="supplementary-material"}A). Sensitive criteria were used in each analysis apart from where indicated. Data from "stringent" criteria that examined only proteins quantified in all three replicates with an average fold change \> 2 and p \< 0.05 are shown in [Table S2](#mmc3){ref-type="supplementary-material"}C. For proteins quantified in all three replicates, a Benjamini-Hochberg-corrected two-tailed t test was used to estimate p values. Only proteins quantified in all three replicates are shown in this scatterplot.(D) Example of a previously unreported target of VACV infection. Data are represented as mean ± SEM; ^∗^p \< 0.05 (see [STAR Methods](#sec4){ref-type="sec"}). Immunoblot of HFFF-TERTs infected with VACV (MOI = 5) confirmed rapid HDAC5 downregulation.

Cell Surface Proteins Targeted by Distinct DNA Viruses to Evade Immunity {#sec2.2}
------------------------------------------------------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID) software package ([@bib24]) was used to identify pathways enriched among proteins downregulated \>2-fold. Interestingly, multiple clusters identified downregulated cell surface receptors and ligands, including the terms "extracellular," "cell attachment site," and "immunoglobulin-like fold" ([Figure 2](#fig2){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}E). This suggests that regulation of plasma membrane proteins may be a key focus of VACV infection.Figure 2Downregulation of Multiple Collagens, Protocadherins, and Innate Immune Mediators(A) Functional enrichment within all proteins that were downregulated \>2-fold at any point during infection compared to 18-h mock samples. A background of all quantified human proteins was used. Shown are representative terms from each cluster with Benjamini-Hochberg-corrected p values of \< 0.05. Components of each significantly enriched cluster are shown in [Table S2](#mmc3){ref-type="supplementary-material"}E. A similar analysis was performed for proteins upregulated \>2-fold; however, this did not reveal any significantly enriched clusters.(B) Example temporal profiles of collagens, innate immune mediators, and protocadherins. Data are represented as mean ± SEM (n = 3); ^∗^p \< 0.05 and ^∗∗^p \< 0.01 (see [STAR Methods](#sec4){ref-type="sec"}). Error bars and statistics are not included on the plots for PCDHGA6, PCDHGB4, and PCDHB8, as these proteins were not quantified in all three replicates; full data are shown in [Table S1](#mmc2){ref-type="supplementary-material"}.(C) Validation of temporal profiles shown in (B) by immunoblot of HFFFs infected with VACV (MOI = 5). Viral proteins D8 and C6 were representative of late and early gene expression, respectively.

Poxviruses devote a considerable proportion of their coding capacity to manipulating host immunity ([@bib6]). Cowpox virus and myxoma virus downregulate surface major histocompatibility complex (MHC) class I ([@bib19]), VACV protein A40 resembles a C-type lectin and some NK cell receptors ([@bib85]) and contributes to virulence ([@bib78]), and VACV protein N1 may limit NK cell activity ([@bib27]). However, there has been no systematic analysis of how VACV modulates NK or T cell recognition, in particular which ligands may be regulated in the infected cell. Therefore, these data were analyzed to determine which known NK and T cell ligands are down- or upregulated during infection. This revealed previously unrecognized modulation of multiple proteins. HLA-A, -B, and -C molecules were all downregulated during infection, in addition to nectin2, the ligand for activating NK receptor DNAM-1, and ULBP2, the ligand for activating NK receptor MHC class I polypeptide-related sequence A (MICA). The tumor necrosis factor (TNF) receptor superfamily member TNFRSF1A was also strongly downregulated ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

Most NK and T cell ligands belong to one of a few protein families, including immunoglobulins, C-type lectins, cadherins, TNF receptors, and major histocompatibility-complex-related molecules ([@bib80]). To identify candidate ligands that have not been recognized previously, we added InterPro functional domain annotations to our data ([@bib25]) and reasoned that modulation of a ligand during VACV infection may indicate biological importance. This showed that 37 proteins had a relevant InterPro annotation and were at least 2-fold downregulated compared to mock infection. Twelve collagens and four protocadherins were downregulated, in addition to the tyrosine protein kinase receptor AXL, endosialin (CD248), and numerous other molecules involved in adhesion, signaling, and immunity ([Figures 2](#fig2){ref-type="fig"}A--2C and [S2](#mmc1){ref-type="supplementary-material"}B--S2D; [Table S3](#mmc4){ref-type="supplementary-material"}).

Certain proteins important in immunity are targeted by more than one, or sometimes multiple, viruses ([@bib63], [@bib64]). To identify proteins jointly downregulated by VACV and an unrelated double-stranded DNA (dsDNA) virus, these data were combined with our previous quantitative temporal analysis of human cytomegalovirus (HCMV) infection ([Figure 3](#fig3){ref-type="fig"}A; [Table S4](#mmc5){ref-type="supplementary-material"}A). The DAVID software suggested that proteins downregulated by both viruses were also enriched in cell surface receptors ([Figure 3](#fig3){ref-type="fig"}B; [Tables S4](#mmc5){ref-type="supplementary-material"}B and S4C). Previously, we identified HCMV-induced downregulation of multiple protocadherins and provided initial evidence that members of this family are activating NK cell ligands ([@bib84]). Protocadherin γB5 was also downregulated during VACV infection, suggesting that this molecule might have a particularly important role in innate immunity ([Figure 3](#fig3){ref-type="fig"}C). Eleven collagens were downregulated by both viruses, and for two of these this was confirmed by immunoblot ([Figure 2](#fig2){ref-type="fig"}C). Certain collagens may be ligands for the inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) ([@bib33]), suggesting that their downregulation may be consistent with an appropriate response to intracellular infection. Given that certain NK ligands can have distinct roles depending on which receptor they bind ([@bib80]), such broad collagen downregulation might equally be specifically triggered by VACV to engender immune evasion.Figure 3Co-regulation of Proteins by VACV and HCMV(A) Overlap between VACV and HCMV whole cell lysate proteomic data ([@bib84]).(B) DAVID enrichment analysis of 85 co-regulated proteins against a background of all 7,289 proteins quantified in both studies.(C) Example temporal profiles of proteins from enriched clusters. For VACV data, data are represented as mean ± SEM (n = 3); ^∗^p \< 0.05 and ^∗∗^p \< 0.01 (see [STAR Methods](#sec4){ref-type="sec"}).

Downregulation of Antiviral Factors and Interferon-Stimulated Genes {#sec2.3}
-------------------------------------------------------------------

Enrichment analysis revealed marked downregulation of proteins in the category "innate immunity" ([Figure 2](#fig2){ref-type="fig"}B; [Table S2](#mmc3){ref-type="supplementary-material"}E). This included IFITM3, which has recently been reported to be downregulated by VACV to evade IFITM3-mediated antiviral restriction ([@bib34]). Strikingly, multiple IFITs were also downregulated; a comprehensive search revealed that all four canonical IFITs 1, 2, 3 and 5 were rapidly downregulated during infection ([Table S2](#mmc3){ref-type="supplementary-material"}A). The IFITs are induced upon stimulation with IFN or viral infection, have homologs in multiple vertebrate species, and play key roles in restricting a diversity of RNA viruses including Rift Valley fever virus (RVFV), vesicular stomatitis virus (VSV), and influenza A ([@bib81]). The canonical mechanism of IFIT restriction is thought to be recognition of RNA modified via 5′ triphosphorylation, or lacking methylation at the 2′-*O* of the 5′ guanosine. Direct inhibition of RNA viral translation has also been reported ([@bib11], [@bib55]). Our observation that both VACV and HCMV downregulate IFITs ([Figure 3](#fig3){ref-type="fig"}C; [Table S4](#mmc5){ref-type="supplementary-material"}C) suggests that this whole class of proteins may have an as yet unrecognized mechanism of restricting DNA viruses in addition to RNA viruses.

We quantified 29 tripartite motif containing proteins (TRIMs), of which TRIM 5, 13, 25, 26, and 56 were downregulated during infection. TRIM5 was also targeted by HCMV ([Figure 3](#fig3){ref-type="fig"}C; [Tables S2](#mmc3){ref-type="supplementary-material"}A and S2B). TRIM5 can restrict retroviruses, and TRIM56 inhibits diverse RNA viruses including influenza, dengue, and yellow fever virus ([@bib35], [@bib36], [@bib57]). Interestingly, TRIM56 has recently also been shown to mono-ubiquitylate the cytosolic sensor cyclic GMP-AMP (cGAMP) synthase (cGAS), resulting in a marked increase in cGAMP production. Mice deficient in TRIM56 exhibited increased susceptibility to lethal infection by herpes simplex virus type 1 (HSV-1) ([@bib65]). It is therefore possible that downregulation of TRIM56 by VACV represents another mechanism of viral evasion of DNA sensing pathways, and suggests that further examination of the IFITs, IFITMs, and TRIMs may identify DNA viral restriction factors, or components of antiviral pathways.

Temporal Analysis of Vaccinia Viral Protein Expression {#sec2.4}
------------------------------------------------------

Recent studies of temporal VACV gene expression have employed transcriptional approaches including microarrays ([@bib1]), RNA sequencing (RNA-seq) ([@bib87], [@bib89]), and most recently a combination of mRNA-seq and ribosomal profiling ([@bib90]). These have enabled an updated classification of viral transcripts, including the definition of early transcript classes E1.1 and E1.2 ([@bib87], [@bib89]). Furthermore, [@bib10] infected a murine bone marrow-derived dendritic-like cell line DC2.4 to quantify 101 VACV proteins over two independent time courses up to 9 h after infection, classifying four protein expression clusters.

A high-definition temporal study of viral protein expression over the whole course of viral infection has the potential to provide a complementary system of protein classification, in addition to enabling direct correlation between viral and cellular protein profiles to give insights into viral-host protein interaction ([@bib84]). We quantified ∼80% of all predicted VACV proteins. The number of classes of viral protein expression was determined by clustering viral proteins using the k-means method, which suggested that there are at least four distinct temporal protein profiles of viral protein expression ([Figures 4](#fig4){ref-type="fig"}A--4C; proteins of each class are shown in [Figures 4](#fig4){ref-type="fig"}D and 4E and [Table S5](#mmc1){ref-type="supplementary-material"}).Figure 4Definition of Temporal Classes of VACV Gene Expression(A) Number of temporal classes of VACV gene expression. The k-means approach was used with 1--15 classes to cluster viral proteins, and the summed distance of each protein from its cluster centroid was calculated. Although this summed distance necessarily becomes smaller as more clusters are added, the rate of decline decreases with each added group, eventually settling at a fairly constant rate of decline that reflects overfitting; clusters added prior to this point reflect the underlying structure in the temporal protein data, whereas clusters subsequently added through overfitting are not informative. The point of inflexion fell between four and six classes, suggesting that there are at least four distinct temporal protein profiles of viral protein expression.(B) Class centroid profiles.(C) Number of viral proteins per class, and the number of proteins in each class whose expression was reduced \>1.5-fold by incubation with AraC (treated and untreated samples both assessed at 6 h of infection; see schematic in [Figure 1](#fig1){ref-type="fig"}A and results in [Figure S3](#mmc1){ref-type="supplementary-material"}).(D) Temporal profiles of proteins in each k-means class were subjected to hierarchical clustering by Euclidian distance.(E) Temporal profiles of representative proteins from each cluster. Data are represented as mean ± SEM (n = 3).(F) Comparison of viral protein and transcript classes.(G) Functional analysis of viral proteins, based on information from [@bib87] and other references detailed in [Table S5](#mmc6){ref-type="supplementary-material"}.

To directly compare transcriptional and protein temporal classes, viral protein expression was examined first in the presence of cytosine arabinoside (AraC). None of the proteins in the earliest temporal class (temporal profile 1, Tp1) were inhibited by AraC, compared to \>70% of proteins in the latest class (Tp4). Proteins that were not apparently inhibited by AraC in the latest class may simply reflect the stringent threshold employed, or the time point of harvesting of AraC-treated samples. We next compared our protein-level data with an RNA-seq-based definition of transcriptional classes from the manuscripts of [@bib87], [@bib89]). Comparison to the protein data was striking: 18/18 Tp1 proteins were E1.1 or E1.2 class transcripts, and 60/69 Tp4 proteins were I or L transcripts (p \< 0.0001, Fisher's exact test). The Tp2 class of proteins was additionally enriched in E1.2 transcripts ([Figures 4](#fig4){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}A; [Table S5](#mmc6){ref-type="supplementary-material"}). Such correspondence between different studies targeting distinct classes of biomolecules suggests that the temporal classes of VACV protein expression defined here are likely to be biologically relevant, and suggests that the temporal regulation of VACV gene expression is chiefly exerted at the transcriptional level. The comparison also highlights some interesting differences. For example, certain transcripts produced early during infection were not expressed maximally until later as Tp3-class proteins, including DNA-dependent RNA polymerase subunits E4 and G5.5, and G2, which has roles in post-replicative transcription elongation ([Figure S4](#mmc1){ref-type="supplementary-material"}A, cluster 3). This suggests that additional mechanisms for temporal regulation of virus gene expression might operate during infection.

Additionally, our data were compared to 47 viral proteins that were assigned the same temporal class in each of two time courses by [@bib10]. These proteins exhibited similar classifications between both studies: 4/5 Tp1 proteins were Croft et al. temporal class 1 and 19/20 Tp4 proteins were Croft et al. temporal classes 3 or 4 ([Figure S4](#mmc1){ref-type="supplementary-material"}B; [Table S5](#mmc6){ref-type="supplementary-material"}).

To further compare protein function with temporal class, we annotated our viral protein data with functions derived from a summary of multiple literature sources ([Table S5](#mmc6){ref-type="supplementary-material"}). The category "virion association," which included virion structural proteins or proteins involved in virion morphogenesis chiefly related to the Tp4 class, while "DNA replication" (including enzymes involved in nucleotide precursor synthesis, DNA replication, and DNA processing) related to Tp2 proteins. Proteins functioning in "host interaction" (including the vaccinia growth factor \[VGF\] and immune evasion proteins) were mainly expressed early ([Figure 4](#fig4){ref-type="fig"}G).

Systematic Analysis of Protein Degradation during VACV Infection {#sec2.5}
----------------------------------------------------------------

Previously, we described a multiplexed approach to discover proteins with innate immune function on the basis of active degradation by the proteasome during HCMV infection ([@bib49]). This approach was adapted to determine which of the proteins that are downregulated by VACV are also proteasomally degraded. MG132 or DMSO was added 2 h after VACV or mock infection to enable virus uncoating in the host cells prior to inhibition of the proteasome. An MG132 "rescue ratio" for each of 8,263 quantified proteins was obtained by comparing protein abundance during VACV infection ± inhibitor with protein abundance during mock infection ± inhibitor. This ratio enabled identification of proteins that exhibited increased degradation during VACV infection, as opposed to those having a high baseline turnover in mock-infected cells. Of the proteins downregulated \>2-fold, 69% had a rescue ratio \>1.5 with p \< 0.05, suggesting that one of the predominant mechanisms VACV employs to downregulate proteins is proteasomal degradation ([Figure 5](#fig5){ref-type="fig"}A). All IFITs, TRIMs, and Ephrin receptors downregulated \>2-fold were rescued by MG132. By contrast, only COL6A2 proteins (isoforms 1 and 2) were rescued; six other downregulated collagens did not meet the criteria for rescue, suggesting an alternative mechanism of downregulation ([Figures 5](#fig5){ref-type="fig"}A and 5B; [Table S6](#mmc7){ref-type="supplementary-material"}A).Figure 5Systematic Analysis of Proteasomal Degradation(A) Scatterplot to identify human proteins that are both downregulated during VACV infection and rescued by proteasomal inhibition. Cells were infected at MOI 5 for 12 h in biological triplicate. MG132 or DMSO control was added 2 h after infection.(B) A "rescue ratio" was calculated: (protein abundance during VACV infection with MG1322 / abundance during infection without MG132) (b) / (protein abundance during mock infection with MG132 / abundance without MG132) (a). Here, (a) was limited to a minimum of 1 to avoid artificial ratio inflation. To fit the constraints of an 11-plex TMT experiment, mock samples (± MG132) were examined in single replicates ([Table S7](#mmc8){ref-type="supplementary-material"}B). For each protein, a Benjamini-Hochberg-corrected two-tailed t test was used to estimate a p value where the infected samples with MG132 were different from the infected samples without MG132. Proteins that exhibited \>2-fold downregulation during infection, a rescue ratio \>1.5-fold, and p \< 0.05 are colored purple. Data underlying this figure are shown in [Table S6](#mmc7){ref-type="supplementary-material"}A.(B) Example data for host proteins that were rescued by proteasomal inhibition. The p values for virally infected biological triplicates were calculated as described in (A). For infected samples, data are represented as mean ± SEM; ^∗^p \< 0.001 and ^∗∗^p \< 0.0005 (see [STAR Methods](#sec4){ref-type="sec"}).(C) Regulation of viral proteins by proteasome inhibition. Data underlying this figure are shown in [Table S6](#mmc7){ref-type="supplementary-material"}B. Three proteins were quantified in this experiment, but not in any of the three time course replicates, and are indicated in black.

Consistent with previous reports, MG132 inhibited late gene expression, but not expression of early genes ([@bib62], [@bib75]). Furthermore, dividing viral proteins into temporal classes revealed that most Tp1 and some Tp2 proteins were upregulated by MG132; Tp3 class proteins were largely unaffected, and Tp4-class proteins were inhibited ([Figure 5](#fig5){ref-type="fig"}C). This suggests that many of the earliest-expressed VACV proteins may be proteasomally degraded. Given that Tp1 and Tp2 class proteins are enriched in "host interaction" functions ([Figure 4](#fig4){ref-type="fig"}G), this may partly be explained by co-degradation of some of these viral proteins with their host targets. Otherwise, the upregulation of some Tp1 and Tp2 proteins might be a consequence of the inhibition of viral DNA replication and post-replicative gene expression by MG132, leading to a prolonged accumulation of early viral mRNAs and their protein products ([@bib2], [@bib52])

Identification of Candidate Viral-Host Interactions {#sec2.6}
---------------------------------------------------

VACV has a dsDNA genome of 191 kbp and is predicted to encode \>200 proteins ([@bib17]). Identification of which viral protein targets a given cellular factor can therefore be a challenging task. We recently described an approach that makes direct comparison between viral and cellular protein profiles ([@bib84]). HDAC5 was rapidly degraded during infection ([Figure 1](#fig1){ref-type="fig"}D), was one of the proteins most substantially rescued by MG132 ([Figures 5](#fig5){ref-type="fig"}A and [6](#fig6){ref-type="fig"}A), and was also downregulated by HCMV, suggesting that this molecule might be particularly important in the life cycle of diverse viruses ([Tables S2](#mmc3){ref-type="supplementary-material"}A and [S4](#mmc5){ref-type="supplementary-material"}B). To determine which class of viral protein targets HDAC5, we compared the four protein class centroid profiles ([Figure 4](#fig4){ref-type="fig"}B) to an inverted profile of HDAC5. This most closely matched Tp2 class proteins ([Figure 6](#fig6){ref-type="fig"}B), suggesting that one of the 38 proteins in this class may target HDAC5.Figure 6VACV Protein C6 Downregulates HDAC5(A) HDAC5, but not HDAC1, is proteasomally degraded during VACV infection. Bar charts and statistics were generated as described in [Figure 5](#fig5){ref-type="fig"}.(B) Viral class centroid profiles compared to an inverted profile of HDAC5, which had additionally been scaled from 0 to 1.(C) Profile of HDAC5 scaled as in (B), and Tp2-class VACV proteins with known roles in regulation of IFN or ISGs.(D) C6 targets HDAC5. HFFF-TERTs were infected in biological triplicate with WT VACV or vΔC6 (lacking gene *C6L*) ([@bib79]) (MOI = 5 and 12 h). The scatterplot shows all proteins quantified. A Benjamini-Hochberg-corrected two-tailed t test was used to estimate p values.(E) Representative immunoblot demonstrating that C6 specifically targets HDAC5. By comparison, HDAC1 was unmodified (MOI = 5). Quantitation of all three replicate immunoblots are shown (right panel). Data are represented as mean ± SEM, ^∗^p \< 0.05 from a two-tailed t test.(F) Representative immunoblot demonstrating rescue of HDAC5 expression by inhibition of the proteasome (MOI = 5). MG132 was added 2 h after VACV infection. Quantitation of all three replicate immunoblots is shown (right panel). Data are represented as mean ± SEM, ^∗∗^p \< 0.00005 from a two-tailed t test.(G) Immunoblot demonstrating that inducible expression of C6 is sufficient for HDAC5 degradation. HEK293T cells inducibly expressing C6 with an N-terminal Myc or C-terminal TAP tag were either treated or untreated with 100 ng/ml doxycycline overnight then lysates immunoblotted.

HDAC5 Is Targeted by the VACV C6 Protein {#sec2.7}
----------------------------------------

To determine which viral protein targets HDAC5, we compared the profiles of the Tp2-class viral proteins known to have roles in innate immune signaling to the profile of HDAC5. Using Euclidian distance as a measure of difference between protein profiles, the expression kinetics of protein C6 most closely matched the kinetics of HDAC5 downregulation ([Figure 6](#fig6){ref-type="fig"}C). An unbiased proteomic comparison of HFFF-TERTs infected with wild-type (WT) VACV or a mutant lacking the *C6L* gene ([@bib79]), vΔC6, showed that HDAC5 was targeted by C6 ([Figure 6](#fig6){ref-type="fig"}D; [Table S1](#mmc2){ref-type="supplementary-material"}). The specific regulation of this HDAC was confirmed by a lack of any effect of infection with either virus on HDAC1 ([Figures 6](#fig6){ref-type="fig"}A and 6E; [Table S1](#mmc2){ref-type="supplementary-material"}).

The proteomic findings that the ubiquitin-proteasome system is co-opted by VACV to degrade HDAC5 ([Figure 6](#fig6){ref-type="fig"}A) was confirmed by immunoblot analysis. MG132 reduced late gene expression, represented by protein D8, but not expression of early protein C6 ([@bib62], [@bib75]), and inhibited HDAC5 degradation ([Figure 6](#fig6){ref-type="fig"}F). Furthermore, HDAC5 downregulation was also observed in the presence of AraC at 6, 12, and 24 h, indicating that an early gene was necessary and intermediate and late gene expression were not needed ([Figure 1](#fig1){ref-type="fig"}D). C6 was also shown to be sufficient for HDAC5 degradation by its inducible expression in HEK.TetR cells ([Figure 6](#fig6){ref-type="fig"}G).

HDAC5 Restricts VACV and HSV-1 Infection {#sec2.8}
----------------------------------------

The rapid downregulation of HDAC5 by VACV early during infection, and downregulation by a distinct large DNA virus, HCMV, suggested a role in antiviral restriction. This was confirmed by the observation that inducible overexpression of HDAC5 in U2OS cells restricted replication of both VACV and HSV-1 ([Figures 7](#fig7){ref-type="fig"}A and 7B). Further, in four independently derived CRISPR/Cas9 knockout clones (in HeLa and HEK293T cells), the replication of both viruses was enhanced compared to control ([Figures 7](#fig7){ref-type="fig"}C--7H). Re-introduction of HDAC5 restored restriction of these viruses ([Figure 7](#fig7){ref-type="fig"}E). Collectively, these data show that HDAC5 is a restriction factor for two different large DNA viruses, and the biological importance of this is supported by the targeted degradation of HDAC5 during VACV and HCMV infection.Figure 7HDAC5 Restricts VACV and HSV-1 Infection(A) Diminished replication of VACV and HSV-1 in an U2OS cell line inducibly expressing HDAC5-FLAG. Infections were performed at MOI = 0.001, for 2 days with VACV and 3 days with HSV-1, after induction with 100 ng/ml doxycycline overnight. Data are represented as mean ± SEM, p values were calculated using a two-tailed t test (n = 3). ^∗^p \< 0.05 and ^∗∗^p \< 0.01; ns: not significant.(B) Immunoblot of HDAC5-FLAG expression in U2OS cell lines.(C) Enhanced replication of VACV and HSV-1 in HeLa CRISPR/Cas9 HDAC5^−/−^ knockout clones compared to parental cell lines. Infections were performed as detailed in (A). Data are represented as mean ± SEM, p values were calculated using a two-tailed t test (n = 3). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.(D) Immunoblot confirmed knockout of HDAC5. Sequencing of genomic DNA from clones H5KO1 and H5KO2 confirmed frameshift mutations in both alleles ([Table S7](#mmc8){ref-type="supplementary-material"}A).(E) Reintroduction of HDAC5 in HDAC5^−/−^ cells restored restriction of VACV and HSV-1 replication. H5KO1 cells were transduced with either empty vector (EV) or HDAC5-FLAG. Infections were performed as detailed in (A). Data are represented as mean ± SEM, p values were calculated using a two-tailed t test (n = 3). ^∗∗∗^p \< 0.001 and ^∗∗∗∗^p \< 0.0001.(F) Immunoblot analysis of HDAC5-FLAG expression in H5KO1 cell lines.(G) Enhanced replication of VACV and HSV-1 in HEK293T CRISPR/Cas9 HDAC5^−/−^ knockout clones compared to parental cell lines. Infections were performed as detailed in (A). Data are represented as mean ± SEM, p values were calculated using a two-tailed t test (n = 3). ^∗^p \< 0.05 and ^∗∗^p \< 0.01.(H) Immunoblot confirming knockout of HDAC5. Sequencing of genomic DNA from clones H5KO3 and H5KO4 confirmed frameshift mutations in both alleles ([Table S7](#mmc8){ref-type="supplementary-material"}A).

Discussion {#sec3}
==========

Recent advances in quantitative proteomics have provided the opportunity to deepen our understanding of variations in the cellular proteome under physiological or pathological conditions. Until now there have been only two proteomic analyses of host and viral proteins during VACV infection, both limited by the technology available to the investigators at the time. In the first, only 24 human and 3 viral proteins were quantified due to the use of two-dimensional gel electrophoresis to pick individual protein spots for analysis ([@bib3]). In the second, a total of ∼3,400 proteins were quantified at a single late time after infection. However, nearly all of the proteins that changed in response to infection were viral gene products, with very little modulation of the host proteome observed ([@bib8]). In this study, we applied quantitative temporal viromics ([@bib84]) to take a comprehensive view of the changes in the viral and cellular proteomes throughout VACV infection. We labeled peptides with TMT tags and measured proteins using MS3 on an Orbitrap Lumos, which can provide a uniquely precise quantitative measurement of protein abundances on a near-global proteomic scale ([@bib77]). Our data thus provide a valuable resource for future studies of poxvirus infection.

To replicate in the cytoplasm, poxviruses have developed multiple strategies to modulate intrinsic host defenses. One benefit is that VACV infection can be used to discover facets of host immunity, because viral modulation of the host often reflects biological importance. Multiple members of certain protein families were regulated during infection, suggesting that these proteins may play a particularly important role in host defense. For example, multiple collagens and protocadherins were downregulated, some of which may be NK ligands. Nevertheless, only 265/8,991 proteins were downregulated \>2-fold even during late infection, despite the profound shutdown of host protein synthesis induced by the virus ([@bib46], [@bib53], [@bib54], [@bib59], [@bib72]). This is in contrast to our previous study of HCMV infection (which does not cause host shutoff), in which 1,740/7,491 proteins were downregulated \>2-fold ([@bib84]). HCMV and VACV have a broadly similar number of canonical genes. The differential regulation of the host observed might therefore reflect differences in viral biology. We have shown that certain individual herpesviral proteins can regulate multiple host targets. For example, HCMV US2 can alone regulate ≥ 21 proteins including MHC molecules and integrins, and a single Kaposi's sarcoma herpesvirus protein, K5, can regulate 83 cell surface proteins ([@bib23], [@bib76]). It is possible that VACV proteins each individually have a paucity of discrete functions; thus, the summed effect of ∼200 viral genes is relatively modest. Nevertheless, C6 had at least 3 targets including E3 ubiquitin ligase RNF114 and Cerebellar degeneration-related protein 2 (CDR2) ([Figure 6](#fig6){ref-type="fig"}D). Alternatively, the degree of regulation of the host by VACV may be small in comparison to HCMV. Since all herpesviruses exhibit latent as well as lytic infection, and must enter and exit the nucleus during lytic replication, such increased complexity to the viral life cycle may also require increased regulation of the infected cell.

One benefit of quantifying common protein changes induced by distinct classes of viruses is the prediction of molecules of particular importance in immunity. The finding that HDAC5 is downregulated by both HCMV and VACV suggested that this molecule might play an important role during infection, such as in antiviral restriction. We demonstrate that HDAC5 indeed restricts both VACV and HSV-1. Previously, HDAC5 was reported to interact with proteins from other viruses, although had not hitherto been identified as a restriction factor, or shown to be downregulated during infection. The HSV-1 immediate protein ICP0 interacted with HDAC5 and inhibited its repression of the cellular myocyte enhancer factor 2 (MEF2) promoter ([@bib39]). HDAC5 could repress activation of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) promoter by the EBV protein EBNA2. Repression was overcome by the co-activator EBNA-LP ([@bib56]). Potential mechanisms that could explain restriction by HDAC5 of viruses replicating in distinct cellular niches therefore include inhibition of viral promoters (via HDAC5 nucleocytoplasmic shuttling) or, possibly, modulation of the IFN pathway or other innate immune signaling pathways. This is under investigation in our laboratory. The VACV C6 protein regulates both IRF-3 and type I IFN signaling and co-precipitates with the TBK1 adaptor proteins SINTBAD, NAP1, and TANK ([@bib79]), and with STAT2 via the transactivation domain (TAD) ([@bib73]). HDAC5 is also known to co-precipitate with STAT2 ([@bib50]). Future studies will address if and how HDAC5 is ubiquitinated, and how C6 interacts with HDAC5, E2, and E3 ligases and any other required accessory proteins.

Mechanisms for protein downregulation by VACV include the well-described host shutoff via viral decapping enzymes and XRN1 mediated degradation of host transcripts ([@bib5], [@bib38], [@bib53], [@bib54], [@bib59], [@bib87]). However, given that the great majority of cellular proteins did not decrease in abundance, a general reduction in mRNA levels, or translation of these, was unlikely to be the major cause of the 265 proteins being reduced more than two fold. Indeed, we found that MG132 rescues 69% of host proteins from degradation including HDAC5, suggesting that many of the downregulated proteins may be specifically targeted to the proteasome. This finding is consistent with a recent analysis of protein ubiquitylation during cowpox virus infection ([@bib18]). Transcriptional mechanisms may nevertheless play an important role in protein downregulation. For example, all collagens downregulated \>2-fold by VACV apart from COL6A2 were not degraded in the proteasome. In our previous analysis of protein degradation during HCMV infection, 10/11 collagens downregulated \>2-fold were transcriptionally, and not proteasomally regulated ([@bib49]). This suggests either that both viruses regulate this class of molecules similarly or that transcriptional repression of collagen expression is a cellular response to infection.

In addition to HDAC5, we found that all IFITs and certain TRIMs were rapidly degraded during infection. IFIT1 mRNA and protein was very recently demonstrated to be downregulated by 24 h of VACV infection, in part via mammalian target of rapamycin (mTOR)-dependent cGAS degradation ([@bib44]). Restriction of VACV by IFITs and TRIMs would highlight additional viral strategies to usurp IFN-mediated antiviral effectors. Candidate viral effectors include the Tp2-class C9 protein, which was recently mapped as an antagonist of IFN action and shown to co-precipitate with components of the SCF (SKP, cullin-1, F-box) E3 ligase complex ([@bib37]). Host targets that may be degraded by C9 are not yet described; however, of note is that C9 itself was significantly upregulated by MG132 ([Table S1](#mmc2){ref-type="supplementary-material"}), which may suggest it is co-degraded ([@bib49]). In addition to viral uncoating, the proteasome has been shown to be required for VACV DNA replication; however, it had hitherto been unclear why ([@bib45], [@bib62], [@bib75]). A possible explanation may be to overcome HDAC5 restriction and to permit virus infection to progress beyond genome replication. Alternatively, proteasome activity may be necessary to directly regulate viral or cellular proteins involved in replicating viral DNA in cytoplasmic viral factories.

The temporal quantitation of ∼80% of predicted VACV proteins in a single experiment provides a substantial advance. Understanding of VACV gene expression had hitherto mainly been at the transcript level. We now provide a temporal system of classification of VACV protein expression complementary to and consistent with the transcriptionally based E1.1/E1.2/I/L nomenclature. A particular use of these temporal protein profiles is the ability to correlate viral and host protein expression, which can predict the class of viral proteins responsible for modulation of each host protein. With additional functional information, such as a knowledge of which proteins in each class can modulate IFN, the individual viral gene required can readily be identified, as shown here for the degradation of HDAC5 by C6.

Using a powerful multiplexed proteomics approach, we have therefore identified VACV cellular targets, and defined protein C6, a multifunctional IFN antagonist, as a factor inducing proteasomal degradation of multiple host restriction factors. In addition to inhibiting IRF-3 activation and type I IFN-induced signaling, C6-induced degradation of HDAC5 joins the increasing panoply of functions encoded by VACV to evade viral restriction.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-IFIT1Thermo Fisher ScientificCat\#PA3-848; RRID:[AB_1958733](nif-antibody:AB_1958733){#intref0010}Mouse monoclonal anti-IFITM1/2/3Santa Cruz BiotechnologyCat\#sc-374026; RRID:[AB_10916884](nif-antibody:AB_10916884){#intref0015}Mouse monoclonal anti-COL6A2Santa Cruz BiotechnologyCat\#sc-374566; RRID:[AB_10991101](nif-antibody:AB_10991101){#intref0020}Mouse monoclonal anti-COL1A2Santa Cruz BiotechnologyCat\#sc-376350; RRID:[AB_10989920](nif-antibody:AB_10989920){#intref0025}Mouse monoclonal anti-TRIM5Santa Cruz BiotechnologyCat\#sc-373864; RRID:[AB_10918111](nif-antibody:AB_10918111){#intref0030}Mouse monoclonal anti-HDAC5Santa Cruz BiotechnologyCat\#sc-133225; RRID:[AB_2116791](nif-antibody:AB_2116791){#intref0035}Rat monoclonal anti-α-tubulin (clone YL1/2)SerotecCat\#MCA77G; RRID:[AB_325003](nif-antibody:AB_325003){#intref0040}Rabbit polyclonal anti-C6[@bib79]N/AMouse monoclonal anti-D8 (clone AB1.1)[@bib51]N/AIRDye 680RD-conjugated goat anti-rabbit IgGLI-CORCat\#926-68071; RRID:[AB_10956166](nif-antibody:AB_10956166){#intref0045}IRDye 680LT-conjugated goat anti-mouse IgGLI-CORCat\#926-68020; RRID:[AB_10706161](nif-antibody:AB_10706161){#intref0050}IRDye 800CW-conjugated goat anti-rabbit IgGLI-CORCat\#926-32211; RRID:[AB_621843](nif-antibody:AB_621843){#intref0055}IRDye 800CW-conjugated goat anti-mouse IgGLI-CORCat\#926-32210; RRID:[AB_621842](nif-antibody:AB_621842){#intref0060}IRDye 680LT-conjugated goat anti-rat IgGLI-CORCat\#926-68029; RRID:[AB_10715073](nif-antibody:AB_10715073){#intref0065}PE goat anti-mouse IgG (clone Poly4053)BioLegendCat\#405307; RRID:[AB_315010](nif-antibody:AB_315010){#intref0070}Mouse monoclonal anti-HDAC1Santa Cruz BiotechnologyCat\# sc-81598; RRID:AB\_ 2118083Mouse monoclonal anti-FLAGSigma-AldrichCat\# F3165; RRID:[AB_259529](nif-antibody:AB_259529){#intref0075}Mouse monoclonal anti-MycCell Signaling TechnologyCat\#2276; RRID:[AB_331783](nif-antibody:AB_331783){#intref0080}**Bacterial and Virus Strains**vC6WR (Western Reserve)Laboratory of Geoffrey Smith; described in [@bib79]N/AvΔC6 (derived from Western Reserve)Laboratory of Geoffrey Smith; described in [@bib79]N/AA5GFP VACV (derived from Western Reserve)Laboratory of Geoffrey Smith; described in [@bib7]N/AVP26GFP HSV-1 (derived from s17 strain)Laboratory of Prashant Desai; described in [@bib21]N/A*E. coli* (Stbl3 Chemically Competent Cells)InvitrogenCat\#C737303*E. coli* (Subcloning Efficiency DH5α Competent Cells)InvitrogenCat\#18265-017**Chemicals, Peptides, and Recombinant Proteins**Tandem mass tag (TMT) 10-plex isobaric reagentsThermo Fisher ScientificCat\#90110HPLC waterVWRCat\#23595.328LC-MS grade AcetonitrileMerckCat\#1.00029.2500Formic acidThermo Fisher ScientificCat\#85178MG132AbcamCat\#ab141003DMEMGIBCOCat\#41966-029MEMGIBCOCat\#31095-029FBSPAN BiotechCat\#P30-19375Penicillin/streptomycinGIBCOCat\#15140-122Cytosine arabinoside (AraC)Sigma-AldrichCat\#C6645PolybreneSigma-AldrichCat\#H9268G418BioVisionCat\#1557PuromycinInvivoGenCat\#ant-pr-1Trypsin-EDTAGIBCOCat\#25300-054Bovine serum albuminSigma-AldrichCat\#A7906SaponinSigma-AldrichCat\#S4521HEPES (1M, pH 7.0-7.6)Sigma-AldrichCat\#H0887Guanidine hydrochloride (8M)Thermo Fisher ScientificCat\#24115DL-DithiothreitolSigmaCat\# 43815-1GIodoacetamideSigmaCat\# I1149-5GLysyl EndopeptidaseWakoCat\# 125-02543Trypsin ProteasePierceCat\# 90058HydroxylamineSigmaCat\# 438227Acetonitrile, Extra DryAcros OrganicsCat\# AC364311000cOmplete, EDTA-free Protease Inhibitor CocktailRocheCat\#11836153001PhosSTOP Phosphatase Inhibitor CocktailRocheCat\#04906837001Paraformaldehyde, 16% solution, EM gradeElectron Microscopy SciencesCat\#15710-SCarbenicillinSigma-AldrichCat\#C9231**Critical Commercial Assays**Micro BCA Protein Assay KitThermo Fisher ScientificCat\#23235TOPO TA Cloning Kit for SequencingInvitrogenCat\#K4575J10Pierce BCA Protein Assay KitThermo Fisher ScientificCat\#23227Platinum *Taq* DNA Polymerase High FidelityInvitrogenCat\#11304011QIAamp DNA Mini KitQIAGENCat\#51306**Deposited Data**Unprocessed peptide filesThis paper[https://doi.org/10.17632/wxk9gnw22r.1](10.17632/wxk9gnw22r.1){#intref0085}Raw Mass Spectrometry Data FilesThis paperProteomeXchange Consortium via the PRIDE partner repository, with the dataset identifier PXD012785.**Experimental Models: Cell Lines**Human fetal foreskin fibroblasts (HFFFs) immortalized with human telomerase (HFFF-TERTs)[@bib71]N/ABS-C-1 (African green monkey cell line)ATCCATCC: CCL-26RK~13~ cells (rabbit kidney cell line)ATCCATCC: CCL-37HEK293T (human embryo kidney epithelial cell line)ATCCATCC: CRL-11268HeLa (human cervical adenocarcinoma epithelial cell line)ATCCATCC: CCL-2U-2 OS (human osteosarcoma epithelial cell line)ATCCATCC: HTB-96HDAC5^−/−^ HeLa cell line (clones KO1 and KO2)This paperN/AHDAC5^−/−^ HEK293T cell line (clones KO3 and KO4)This paperN/A**Oligonucleotides**Forward primer for exon 3 of human HDAC5: AGTGGCCTGAGGGAACCTGTGCTGTThis paperN/AReverse primer for exon 3 of human HDAC5: AGGCAGGGACATCAAGGCACTTACThis paperN/AForward primer for exon 4 of human HDAC5: AAAATGTTGCATCCATGGAGCAGThis paperN/AReverse primer for exon 4 of human HDAC5: ATGGGAACGGAGGCACAAGTGAThis paperN/AComplete oligonucleotides including those for CRISPR/cas9 gene disruption.[Table S7](#mmc8){ref-type="supplementary-material"}N/A**Recombinant DNA**pSpCas9(BB)-2A-Puro (px459)[@bib58]Addgene plasmid \#62988pLKOneo.EGFPnlsTetRLaboratory of Roger Everett; [@bib15]N/ApLKO.DCMV.TetO.mcsLaboratory of Roger Everett; [@bib15]N/ApLKO.DCMV.TetO.HDAC5-FLAGThis paperN/ApCMV.dR8.91Laboratory of Heike LamanN/ApMD-GLaboratory of Heike LamanN/A**Software and Algorithms**"MassPike," a Sequest-based software pipeline for quantitative proteomics.Professor Steven Gygi's lab, Harvard Medical School, Boston, USA.N/AXLStatAddinsoft<https://www.xlstat.com/en/>DAVID software[@bib24]<https://david.ncifcrf.gov/>Cluster 3.0Stanford University of Tokyo[http://bonsai.hgc.jp/∼mdehoon/software/cluster/software.htm](http://bonsai.hgc.jp/%7Emdehoon/software/cluster/software.htm){#intref0100}Java TreeviewSourceForge.net<http://jtreeview.sourceforge.net/>Clustal OmegaEMBL-EBI<https://www.ebi.ac.uk/Tools/msa/clustalo/>FlowJo CE (version 7.5.109.8)FlowJo<https://www.flowjo.com/solutions/flowjo>FlowJo (version 10.1r5)FlowJo<https://www.flowjo.com/solutions/flowjo>Perseus (version 1.5.1.6)Max Planck Institute of Biochemistry<http://www.coxdocs.org/doku.php?id=perseus:start>GraphPad Prism 5 for Windows (version 5.04)GraphPad Software<https://www.graphpad.com/>Odyssey Infrared Imaging System (version 3.0.29)LI-COR Biosciences<http://www.licor.com/bio/blog/category/imaging-systems/odyssey-imaging-systems/>AxioVision (version 4.8)ZEISS<https://www.zeiss.com/microscopy/us/downloads/axiovision-downloads.html>**Other**Orbitrap Fusion Lumos Mass SpectrometerThermo Fisher ScientificCat\#IQLAAEGAAP FADBMBHQTrans-Blot Turbo Transfer SystemBio-RadCat\#1704150FACScan flow cytometry analyzer, upgraded to DxP8 by CytekFACScan/CytekN/AOdyssey Infrared Imaging SystemLI-COR BiosciencesCat\#9120ZEISS Axio Vert.A1 fluorescence microscopeZEISSCat\# 491237-0014-000

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael Weekes (<mpw1001@cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cells and Cell Culture {#sec4.3.1}

Primary human fetal foreskin fibroblast cells immortalized with human telomerase (HFFF-TERTs, male), BS-C-1 (African green monkey cell line, ATCC CCL-26), HeLa (human cervical ATCC CCL-2,+ female) parental and HDAC5^−/−^ derivative cell lines, HEK293T (human embryo kidney epithelial cell line, ATCC CRL-11268, female) parental and HDAC5^−/−^ derivative cell lines and human bone osteosarcoma epithelial (U2OS, ATCC HTB-96, female) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with fetal bovine serum (FBS: 10% v/v), and penicillin/streptomycin at 37°C in 5% CO~2~. Transduced U2OS.TetR.HDAC5-FLAG, HEK.TetR.TAPcoC6 and HEK.TetR.MyccoC6 cell lines were additionally supplemented with 500μg/ml G418 and 1 μg/ml puromycin. RK~13~ cells (rabbit kidney cell line, ATCC CCL-37) were maintained in minimal essential medium (MEM) supplemented with 10 % FBS and penicillin/streptomycin.

All cell lines apart from HFFF-TERTs were obtained from and authenticated by ATCC. HFFF-TERTs have been tested at regular intervals since isolation to confirm both that the HLA and MICA genotypes, and the morphology and antibiotic resistances are consistent with the original cells described in ([@bib43]). In addition, HFFF-TERTs are routinely infected with the HCMV Merlin strain, which is only permissive in human fibroblasts (dermal or foreskin), further limiting the chances that the cells have been contaminated with another cell type. HDAC5-deficient HeLa and HEK cell lines were derived from the respective parental cell lines obtained from ATCC. All cell lines used regularly tested negative for mycoplasma.

### Viruses {#sec4.3.2}

Wild-type VACV strain Western Reserve (WR) and a derivative strain lacking the *C6L* gene, or with the capsid protein A5 fused with GFP (A5GFP VACV) were described ([@bib7], [@bib79]). HSV-1 strain s17 with GFP fused to virus protein 26 (VP26GFP) was provided by Prashant Desai ([@bib21]). VACVs were propagated in RK~13~ cells, purified by ultracentrifugation through a 36% (w/v) sucrose cushion and suspended in 10 mM Tris-HCl pH 9.0. VACV infectivity was determined by plaque assay on BS-C-1 cells. VP26GFP HSV-1 was propagated in U2OS cells, and the infectivity was determined by plaque assay on U2OS cells.

### Plasmids {#sec4.3.3}

The CRISPR/Cas9 plasmid px459 was from Addgene, \#62988. Lentivirus vector plasmids pLKOneo.EGFPnlsTetR and pLKO.DCMV.TetO.mcs ([@bib15]) were from Prof. Roger Everett (MRC, Centre for Virus Research, University of Glasgow). Plasmid pLKO.DCMV.TetO.HDAC5-FLAG was constructed by insertion of HDAC5-FLAG sequence with a 5′ HindIII site and a 3′MluI into the multiple cloning site of pLKO.DCMV.TetO.mcs. Plasmids pLKO.DCMV.TetO.TAPcoC6 and pLKO.DCMV.TetO.MyccoC6 were constructed by insertion of TAPcoC6 (carboxyl terminus TAP tag) or MyccoC6 (amino-terminus Myc tag) sequence with a 5′ Sal1 site and a 3′ EcoR1 into the multiple cloning site of pLKO.DCMV.TetO.mcs. Plasmids pCMV.dR8.91 (expressing lentivirus helper functions) and pMD-G (vesicular stomatitis virus envelope protein G) were from Heike Laman (Department of Pathology, University of Cambridge) and were used together with the above lentivirus vectors, to produce lentivirus stocks as described ([@bib15]).

Method Details {#sec4.4}
--------------

### Virus Infections and Inhibitors {#sec4.4.1}

For proteomic experiments, 1 × 10^6^ HFFF-TERTs were seeded in a 25-cm^2^ flask. Cells were infected at MOI 5. All time course experiments (WCL1-3) were performed in biological triplicate. Where indicated cells were incubated with cytosine arabinoside (AraC) at 40 μg/ml from the time of infection. For the experiment comparing wt infection with the derivative lacking the *C6L*, and wt infection in the presence or absence of MG132 ('wt_C6L_MG'), where appropriate, after 2 h, inocula were removed and replaced with fresh medium with or without 10 μM MG132. This experiment was conducted in biological triplicate for wt(-MG132), wt(+MG132) and Δ*C6L*, and in single replicates for mock infection ± MG132 to fit the 11-plex limit of TMT experiments ([Table S7](#mmc8){ref-type="supplementary-material"}B). For immunoblots, 1 × 10^6^ HFFF-TERTs were plated in 6-well plates. Cells were infected or mock infected at MOI 5. After 2 h, inocula were removed and replaced with fresh medium with or without 10 μM MG132.

For virus replication assays, 2 × 10^6^ parental or HDAC5^−/−^ HEK293T cells were seeded in 6-well plates. Cells were infected at MOI 0.001 with A5GFP VACV. After 2 d, both the supernatant and infected cells were collected for titration on BS-C-1 cells. Thus, in [Figure 7](#fig7){ref-type="fig"}G, virus yield is shown without distinction between intracellular and extracellular virions. VP26GFP HSV-1 infections were as above, except supernatants were collected at 3 d p.i. for titration on U2OS. Similar virus infection assays were performed on parental and HDAC5^−/−^ HeLa cells.

To measure GFP positive foci, infected monolayers of parental or HDAC5^−/−^ HeLa cells were infected for 2 d with VACV or 3 d with HSV-1 and then imaged at 50X magnification using a ZEISS Axio Vert.A1 fluorescent microscope and the AxioVision 4.8 software.

### Lentiviral Transduction {#sec4.4.2}

HEK293T cells (3 × 10^6^) were seeded in 10-cm dishes and on the following day were transfected with 3 μg of pLKOneo.EGFPnlsTetR together with 3 μg of each pMD-G and pCMV.dR8.91. After 3 h, the cell culture medium was replaced with DMEM supplemented with 30% FBS and penicillin-streptomycin. After overnight incubation, the cell culture supernatant was collected and replaced with 5 mL of 30% FBS/DMEM. The collected supernatant was passed through a 0.45 μm filter and supplemented with 2 μg/ml polybrene (Sigma-Aldrich, H9268). Lentivirus stock was used to transduce U2OS cells over two successive days. Transduced cells were cultured for 2 days, then the cells were selected with 500 μg/ml G418 (BioVision, 1557), to obtain a cell line stably expressing TetR repressor. The same method was used to introduce HDAC5-FLAG into different cell lines (U2OS-TetR and HDAC5^−/−^) with the plasmid pLKO.TetO.HDAC5-FLAG. The HDAC5-FLAG transduced cells were selected with 1 μg/ml puromycin (InvivoGen, 58-58-2).

### CRISPR/Cas9-Mediated Gene Knockout {#sec4.4.3}

px459 plasmids expressing gRNAs targeting HDAC5 exon 3 and exon 4 were prepared as described ([@bib58]). HeLa or HEK293T cells were seeded in 10-cm dishes and the next day were transfected with 3 μg of either px459.HDAC5E4 or px459.HDAC5E3, expressing gRNAs to target *HDAC5* exons 4 and 3, respectively ([Table S7](#mmc8){ref-type="supplementary-material"}A). The following day, transfected cells were selected in medium with 1 μg/ml puromycin. After 2 days, selection medium was replaced with normal DMEM with 10% FBS. After 5-7 days, the cell population had reached 50%--80% confluence. Cells were detached, serially diluted and seeded into 96-well plates. Single-cell clones were selected for analysis. To confirm gene knockout, lysates from each clone were analyzed by immunoblotting and DNA sequencing of the genomic region targeted by each gRNA. For sequencing, primers were designed to be specific to introns flanking *HDAC5* exon 3 or exon 4 ([Table S7](#mmc8){ref-type="supplementary-material"}A). To identify DNA sequences from each allele, TOPO cloning (Invitrogen, K4575J10) was performed with HDAC5 PCR fragments and 20 colonies from each knockout clone were sequenced. Two HDAC5^−/−^ clones were generated from HeLa parental cells with gRNAs targeting either *HDAC5* exon 4 (H5KO1) or *HDAC5* exon 3 (H5KO2), and two HDAC5^−/−^ clones were generated from HEK293T cells with gRNA targeting *HDAC5* exon4 (H5KO3 and H5KO4). The DNA sequences of the gRNA-targeted regions from the HDAC5^−/−^ clones used are shown in [Table S7](#mmc8){ref-type="supplementary-material"}A and confirmed that each allele of each clone contained frameshifting mutations and that wild-type sequences were not detected.

### Immunoblotting {#sec4.4.4}

Cells were washed with PBS, and scraped in 400 μL cell lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Triton X-100, 0.1% NP-40), supplemented with protease and phosphatase inhibitors cocktails (Roche). Cell lysates were transferred to 1.5 mL eppendorf tubes and clarified by centrifugation at 17,000 *g* at 4°C for 15 min. Protein concentration was measured by BCA assay (Pierce) and protein extracts were reduced with 100 mM DTT in SDS-gel loading buffer for 5 min at 100°C. Equal protein amounts were separated by SDS-PAGE in 8% or 12% polyacrylamide gels, then transferred to nitrocellulose membranes using the Trans-Blot Turbo transfer system (Bio-Rad). The membranes were blocked in 5% non-fat milk in TBS containing 0.1% Tween-20 for 30 min at room temperature. The following primary antibodies were used at the indicated dilution, in blocking solution: rabbit anti-IFIT1 (1:1000, cat. no. PA3-848, Thermo Fisher Scientific), mouse anti-IFITM1/2/3 (1:500, cat. no. sc-374026, Santa Cruz Biotechnology), mouse anti-COL6A2 (1:500, cat. no. sc-374566, Santa Cruz Biotechnology), mouse anti-COL1A2 (1:500, cat. no. sc-376350, Santa Cruz Biotechnology), mouse anti-TRIM5 (1:500, cat. no. SC-373864, Santa Cruz Biotechnology), mouse anti-HDAC5 (1:500, cat. no. sc-133225, Santa Cruz Biotechnology), mouse anti-HDAC1 (1:500, cat. no. sc-81598, Santa Cruz Biotechnology), mouse anti-FLAG, (1:1000, F3165, Sigma-Aldrich), mouse anti-Myc (1:1000, cat. no. 2276, Cell Signaling Technology), rat anti-α-tubulin (1:10,000, clone YL1/2, cat. no. MCA77G, Serotec), rabbit anti-C6 (1:1000, described in ([@bib79]), mouse anti-D8 (1:1000, described in ([@bib51])). The secondary antibodies were from LI-COR Biosciences and were used at 1:10,000 dilution, in blocking solution: IRDye 680RD-conjugated goat anti-rabbit IgG (cat. no. 926-68071), IRDye 680LT-conjugated goat anti-mouse IgG (926-68020), IRDye 800CW-conjugated goat anti-rabbit IgG (926-32211), IRDye 800CW-conjugated goat anti-mouse IgG (926-32210), IRDye 680LT-conjugated goat anti-rat IgG (926-68029). The reactive bands were detected using an Odyssey infrared imager (LI-COR Biosciences).

### Flow Cytometry {#sec4.4.5}

VACV-infected HFFF-TERTs were detached with trypsin-EDTA (GIBCO) 12 h post-infection, washed in PBS and fixed with 4% paraformaldehyde in PBS for 10 min at room temperature with intermittent agitation by vortexing. Fixed cells were collected by centrifugation and suspended in PBS containing 0.1% bovine serum albumin (Sigma). For intracellular staining of VACV protein D8, cells were permeabilised with 0.1% saponin (Sigma) in PBS and stained with the mouse monoclonal antibody AB1.1 specific for the VACV protein D8 ([@bib51]) or isotype control, followed by PE goat anti-mouse IgG (Poly4053, BioLegend). Stained cells were fixed again with 1% paraformaldehyde in PBS. Data were acquired with a FACScan/Cytek DxP8-upgraded flow cytometry analyzer and analyzed with FlowJo software.

### Whole Cell Lysate Protein Digestion {#sec4.4.6}

Cells were washed twice with PBS and 250 μL lysis buffer was added (6 M guanidine / 50mM HEPES pH 8.5). Cell lifters (Corning) were used to scrape cells in lysis buffer, which was removed to an eppendorf tube, vortexed extensively and then sonicated. Cell debris was removed by centrifuging at 21,000 *g* for 10 min, twice. Half of each sample was kept for subsequent analysis by immunoblot where required. For the other half, dithiothreitol (DTT) was added to a final concentration of 5 mM and samples were incubated for 20 min. Cysteines were alkylated with 14 mM iodoacetamide and incubated for 20 min at room temperature in the dark. Excess iodoacetamide was quenched with DTT for 15 min. Samples were diluted with 200 mM HEPES pH 8.5 to 1.5 M guanidine followed by digestion at room temperature for 3 h with LysC protease at a 1:100 protease-to-protein ratio. Samples were further diluted with 200 mM HEPES pH 8.5 to 0.5 M guanidine. Trypsin was then added at a 1:100 protease-to-protein ratio followed by overnight incubation at 37°C. The reaction was quenched with 5% formic acid and then centrifuged at 21,000 *g* for 10 min to remove undigested protein. Peptides were subjected to C18 solid-phase extraction (SPE, Sep-Pak, Waters) and vacuum-centrifuged to near-dryness.

### Peptide Labeling with Tandem Mass Tags {#sec4.4.7}

In preparation for TMT labeling, desalted peptides were dissolved in 200 mM HEPES pH 8.5. Peptide concentration was measured by microBCA (Pierce), and 25 μg of peptide was labeled with TMT reagent. TMT reagents (0.8 mg) were dissolved in 43 μL anhydrous acetonitrile and 3 μL was added to peptide at a final acetonitrile concentration of 30% (v/v). Sample labeling was as indicated in [Table S7](#mmc8){ref-type="supplementary-material"}B. Following incubation at room temperature for 1 h, the reaction was quenched with hydroxylamine to a final concentration of 0.5% (v/v). TMT-labeled samples were combined at a 1:1:1:1:1:1:1:1:1:1:1 ratio. The sample was vacuum-centrifuged to near dryness and subjected to C18 SPE (Sep-Pak, Waters). An unfractionated single shot was analyzed initially to ensure similar peptide loading across each TMT channel, to avoid the need for excessive electronic normalization. As all normalization factors were \> 0.5 and \< 2, data for the WCL2, WCL3 and wt_C6L_MG singleshot experiments were analyzed with data for the corresponding fractions to increase the overall number of peptides quantified. Normalization is discussed in the [Data Analysis](#sec4.5.1){ref-type="sec"} section below, and high pH reversed-phase (HpRP) fractionation is discussed below.

### Offline HpRP Fractionation {#sec4.4.8}

TMT-labeled tryptic peptides were subjected to HpRP fractionation using an Ultimate 3000 RSLC UHPLC system (Thermo Fisher Scientific) equipped with a 2.1 mm internal diameter (ID) x 25 cm long, 1.7 μm particle Kinetix Evo C18 column (Phenomenex). Mobile phase consisted of A: 3% acetonitrile (MeCN), B: MeCN and C: 200 mM ammonium formate pH 10. Isocratic conditions were 90% A / 10% C, and C was maintained at 10% throughout the gradient elution. Separations were conducted at 45°C. Samples were loaded at 200 μl/min for 5 min. The flow rate was then increased to 400 μl/min over 5 min, after which the gradient elution proceed as follows: 0%--19% B over 10 min, 19%--34% B over 14.25 min, 34%--50% B over 8.75 min, followed by a 10 min wash at 90% B. UV absorbance was monitored at 280 nm and 15 s fractions were collected into 96-well microplates using the integrated fraction collector. Fractions were recombined orthogonally in a checkerboard fashion, combining alternate wells from each column of the plate into a single fraction, and commencing combination of adjacent fractions in alternating rows. Wells prior to the start or after the stop of elution of peptide-rich fractions, as identified from the UV trace, were excluded. This yielded two sets of 12 combined fractions, A and B, which were dried in a vacuum centrifuge and resuspended in 10 μl MS solvent (4% MeCN / 5% formic acid) prior to LC-MS3. For all experiments, 12 set 'A' fractions were used.

### LC-MS3 {#sec4.4.9}

Mass spectrometry data was acquired using an Orbitrap Lumos (Thermo Fisher Scientific, San Jose, CA). An Ultimate 3000 RSLC nano UHPLC equipped with a 300 μm ID x 5 mm Acclaim PepMap μ-Precolumn (Thermo Fisher Scientific) and a 75 μm ID x 50 cm 2.1 μm particle Acclaim PepMap RSLC analytical column was used. Loading solvent was 0.1% FA, analytical solvent A: 0.1% FA and B: 80% MeCN + 0.1% FA. All separations were carried out at 55°C. Samples were loaded at 5 μL/min for 5 min in loading solvent before beginning the analytical gradient. The following gradient was used: 3%--7% B over 3 min, 7%--37% B over 173 min, followed by a 4-min wash at 95% B and equilibration at 3% B for 15 min. Each analysis used a MultiNotch MS3-based TMT method ([@bib41], [@bib42]). The following settings were used: MS1: 380-1500 Th, 120,000 Resolution, 2 × 10^5^ automatic gain control (AGC) target, 50 ms maximum injection time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (normalized collision energy (NCE) 35) with ion trap scanning in turbo mode from m/z 120, 1.5x10^4^ AGC target, 120 ms maximum injection time. MS3: In Synchronous Precursor Selection mode the top 6 MS2 ions were selected for HCD fragmentation (NCE 65) and scanned in the Orbitrap at 60,000 resolution with an AGC target of 1 × 10^5^ and a maximum accumulation time of 150 ms. Ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. Dynamic exclusion was set to ± 10 ppm for 70 s. MS2 fragmentation was trigged on precursors 5 × 10^3^ counts and above.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Data Analysis {#sec4.5.1}

In the following description, we list the first report in the literature for each relevant algorithm. Mass spectra were processed using a Sequest-based software pipeline for quantitative proteomics, "MassPike," through a collaborative arrangement with Professor Steve Gygi's laboratory at Harvard Medical School. MS spectra were converted to mzXML using an extractor built upon Thermo Fisher's RAW File Reader library (version 4.0.26). In this extractor, the standard mzxml format has been augmented with additional custom fields that are specific to ion trap and Orbitrap mass spectrometry and essential for TMT quantitation. These additional fields include ion injection times for each scan, Fourier Transform-derived baseline and noise values calculated for every Orbitrap scan, isolation widths for each scan type, scan event numbers, and elapsed scan times. This software is a component of the MassPike software platform and is licensed by Harvard Medical School.

A combined database was constructed from (a) the human UniProt database (26^th^ January, 2017), (b) the VACV strain WR UniProt database (23^rd^ February 2017), (c) common contaminants such as porcine trypsin and endoproteinase LysC. The combined database was concatenated with a reverse database composed of all protein sequences in reversed order. Searches were performed using a 20 ppm precursor ion tolerance ([@bib20]). Product ion tolerance was set to 0.03 Th. TMT tags on lysine residues and peptide N termini (229.162932 Da) and carbamidomethylation of cysteine residues (57.02146 Da) were set as static modifications, while oxidation of methionine residues (15.99492 Da) was set as a variable modification.

To control the fraction of erroneous protein identifications, a target-decoy strategy was employed ([@bib13], [@bib14]). Peptide spectral matches (PSMs) were filtered to an initial peptide-level false discovery rate (FDR) of 1% with subsequent filtering to attain a final protein-level FDR of 1% ([@bib32], [@bib86]). PSM filtering was performed using a linear discriminant analysis, as described ([@bib26]). This distinguishes correct from incorrect peptide IDs in a manner analogous to the widely used Percolator algorithm ([@bib29]), though employing a distinct machine learning algorithm. The following parameters were considered: XCorr, ΔCn, missed cleavages, peptide length, charge state, and precursor mass accuracy. Protein assembly was guided by principles of parsimony to produce the smallest set of proteins necessary to account for all observed peptides ([@bib26]).

Proteins were quantified by summing TMT reporter ion counts across all matching peptide-spectral matches using "MassPike," as described ([@bib41], [@bib42]). A minimum one unique or shared peptide per protein was used for quantitation. Briefly, a 0.003 Th window around the theoretical m/z of each reporter ion (126, 127n, 127c, 128n, 128c, 129n, 129c, 130n, 130c, 131n, 131c) was scanned for ions, and the maximum intensity nearest to the theoretical m/z was used. The primary determinant of quantitation quality is the number of TMT reporter ions detected in each MS3 spectrum, which is directly proportional to the signal-to-noise (S:N) ratio observed for each ion ([@bib40]). Conservatively, every individual peptide used for quantitation was required to contribute sufficient TMT reporter ions (minimum of ∼1250 per spectrum) so that each on its own could be expected to provide a representative picture of relative protein abundance ([@bib41]). Additionally, an isolation specificity filter was employed to minimize peptide co-isolation ([@bib77]). Peptide-spectral matches with poor quality MS3 spectra (more than 9 TMT channels missing and/or a combined S:N ratio of less than 250 across all TMT reporter ions) or no MS3 spectra at all were excluded from quantitation. Peptides meeting the stated criteria for reliable quantitation were then summed by parent protein, in effect weighting the contributions of individual peptides to the total protein signal based on their individual TMT reporter ion yields. Protein quantitation values were exported for further analysis in Excel.

For protein quantitation, reverse and contaminant proteins were removed, then each reporter ion channel was summed across all quantified proteins and normalized assuming equal protein loading across all channels. For further analysis and display in figures, fractional TMT signals were used (i.e., reporting the fraction of maximal signal observed for each protein in each TMT channel, rather than the absolute normalized signal intensity). This effectively corrected for differences in the numbers of peptides observed per protein. For all TMT experiments, normalized S:N values are presented in [Table S1](#mmc2){ref-type="supplementary-material"} ('Data' worksheet).

Hierarchical centroid clustering based on uncentered Pearson correlation was performed using Cluster 3.0 (Stanford University). XLStat (Addinsoft) was used to perform k-means clustering. Each cluster was subjected to hierarchical clustering using Cluster 3.0. Clusters were visualized using Java Treeview (<http://jtreeview.sourceforge.net>).

### Statistical Analysis {#sec4.5.2}

The exact value of n within figures is indicated in the respective figure legends, and refers to the number of biological replicates. Blinding or sample-size estimation was not appropriate for this study. There were no inclusion criteria and no data was excluded.

[Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc1){ref-type="supplementary-material"}, [S3](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}*.* Time course experiments were conducted in biological triplicate (WCL1-3). For experiment wt_C6L_MG, infections with VACV (+/− MG132) and VACV lacking *C6L* were performed in biological triplicate. In this experiment, to fit the constraints of 11-plex TMT, mock samples ± MG132 were examined in single replicates ([Table S7](#mmc8){ref-type="supplementary-material"}B).

For proteins quantified in all three replicates, a two-tailed Student's t test was used to estimate p values that each average fold change was significantly different to 1. Values were calculated in Excel and corrected for multiple hypothesis testing using the method of Benjamini-Hochberg using an Excel macro written by one of the authors. A corrected p value \< 0.05 was considered statistically significant.

[Figures 4](#fig4){ref-type="fig"}, *S4.* XLStat (Addinsoft) was used to calculate the summed distance of each protein from its cluster centroid then perform k-means clustering. Each cluster was subjected to hierarchical clustering using Cluster 3.0 (Stanford University) ([Figure 4](#fig4){ref-type="fig"}A).

[Figures 6](#fig6){ref-type="fig"}E and 6F. Immunoblots were performed in biological triplicate. Two-tailed t tests were used to estimate p values that each mean quantified relative band intensity in the ΔC6 or wt VACV+MG132 was different from control. A p value \< 0.05 was considered statistically significant.

[Figure 7](#fig7){ref-type="fig"}. p values were calculated using two-tailed t tests. A p value \< 0.05 was considered statistically significant.

### Pathway Analysis {#sec4.5.3}

The Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.8 was used to determine pathway enrichment ([@bib24]). Proteins regulated as indicated in the text were searched against a background of all human proteins quantified, using default settings.

Data and Software Availability {#sec4.6}
------------------------------

Unprocessed peptide data files for [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [6](#fig6){ref-type="fig"} are available at [https://doi.org/10.17632/wxk9gnw22r.1](10.17632/wxk9gnw22r.1){#intref0155}. These files include details of peptide sequence, redundancy, protein assignment, raw unprocessed TMT reporter intensities and isolation specificity. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (<http://www.proteomexchange.org/>) via the PRIDE partner repository with the dataset identifier PXD012785.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5Table S1. Interactive Spreadsheet of All Data in the Manuscript, Related to Figures 1, 2, 3, 4, 5, and 6The "Plotter" worksheet enables generation of graphs for all of the human and viral proteins quantified and easy visualization of statistics. The "Data" worksheet shows minimally annotated protein data, with only formatting and normalization modifying the raw data. The "Time course stats" and "MG132 and C6 stats" worksheets shows all derived p values.Table S2. Proteins Modulated during VACV Infection, Related to Figures 1 and 2(A) Proteins downregulated on average \>2-fold at ≥1 time point across all replicates in which the protein was quantified, compared to 18 h mock infection ('sensitive' criteria). (B) All proteins upregulated \>2-fold using "sensitive" criteria. (C) Proteins quantified in all three replicates and downregulated on average \>2-fold at ≥1 time point with p \< 0.05 ("stringent" criteria). (D) Proteins upregulated \>2-fold using "stringent" criteria. (E) Enrichment of functional pathways within proteins shown in (A), compared to all quantified proteins.Table S3. Candidate Immunoreceptors, Related to Figures 2 and S2Table S4. Protein Regulation by VACV and HCMV, Related to Figure 3(A) All proteins quantified in both this study and a previous quantitative temporal analysis of HCMV infection ([@bib84]). (B) All proteins downregulated \>2-fold by both VACV and HCMV, at ≥1 time point during the course of both infections. (C) Enrichment of functional pathways within proteins shown in (B), compared to all quantified proteins shown in (A).Table S5. VACV Protein and Transcriptional Classes, Related to Figure 4Transcriptional classes and functional category information were derived from [@bib87], [@bib90]). A comparison to a prior analysis ([@bib10]) is included in this table. Croft et al. analyzed VACV infection in two independent time courses, with time course 1 from 0.5--9.5 h of infection, sampled at 3 h intervals and time course 2 from 0.5--8.5 h of infection sampled at 2 h intervals. Each generated four temporal classes of viral proteins. As some of these data are discordant, a further column is included in the table indicating concordant temporal classes for 47 viral proteins, to which our data were compared ([Figure S4](#mmc1){ref-type="supplementary-material"}B).Table S6. Systematic Analysis of Proteasomal Degradation, Related to Figure 5(A) Human proteins downregulated \>2-fold at 12 h of VACV infection compared to mock. Rescue ratios are shown as defined in [Figure 5](#fig5){ref-type="fig"}A. (B) Data for all 173 viral proteins quantified in this experiment.Table S7. Confirmation of Genetic Knockout and Details of TMT Labeling, Related to Figure 7 and STAR Methods(A) Confirmation of genetic knockout in independent HeLa and HEK293T HDAC5^−/−^ clones. Sequencing of the genomic region targeted by the gRNAs confirmed frameshift mutations had been introduced into each allele. Primers and gRNA sequences employed are also shown. (B) Details of TMT labeling.Document S2. Article plus Supplemental Information
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